NCT03197493View on ClinicalTrials.gov

Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions
Macula; DegenerationRetina
Interventions
DRUG

carbidopa-levodopa 25-100 mg

High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID

Trial Locations (1)

85712

Robert W Snyder, MD, PhD, PC, Tucson

All Listed Sponsors
collaborator

Snyder Biomedical Corporation

OTHER

lead

Snyder, Robert W., M.D., Ph.D., P.C.

INDIV

NCT03197493 - Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter